Merck delays plan to seek FDA approval for migraine drug

04/21/2009 | Wall Street Journal, The

Merck & Co. said it will postpone its plan to submit migraine drug telcagepant for FDA approval after a clinical trial of patients taking the drug daily showed increased levels of liver enzymes. Merck halted the study but is continuing other trials focused on the drug's use in managing periodic migraines, a company official said.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ